Abstract

Purpose: The purpose of our study is to retrospectively review our institutional experience with adult rhabdomyosarcoma (RMS) to determine presentation, prognostic factors and patterns of failure in this disease. Materials and Methods: All patients ≥ 16 years with a diagnosis of rhabdomyosarcoma were retrospectively reviewed. Tumors were classified according to the Intergroup Rhabdomyosarcoma Study (IRS) staging and grouping system. Median follow-up for surviving patients was 12.5 years. Results: A total of 39 patients (23 male, 16 female) were seen at our institution from 1961 to 1999. Median age was 45 years, and age distribution showed a bimodal peak at the late teens to twenties and later in the sixties. Tumor in the extremity was most common as seen in 15 (39%); this was followed by head and neck in 11 (28%), genitourinary in eight (20%), trunk/retroperitoneum in four (10%) and other in one (3%). Tumor stage was T1 in 21 (52%) while 26 (67%) were > 5 cm in size. Pleomorphic histology was most common (36%) and increased in incidence according to age category: 0% for ages 16–19, 27% for ages 20–49 and 60% for ages ≥ 50 years old (P < 0.01). The median survival for the entire population was 2.25 years with a 5-year overall survival rate of 35%. Multivariate analysis identified early IRS stage (P < 0.001), non-embryonal histology (P < 0.009), favorable site (P = 0.024), female gender (P = 0.034), early T-stage (P = 0.034) and absence of nodal metastases (P = 0.037) as predictors of a better survival. The 5-year progression-free survival rate was 21%. Female gender (P = 0.002), non-embryonal histology (P = 0.009), early IRS stage (P = 0.02) and early T stage (P = 0.033) were found on multivariate analysis to predict for improved progression-free survival. The 5-year local control rate was 51%, and multivariate analysis found that only early T-stage was predictive of better local control (P = 0.045). Five of six Group II patients and five of eight Group III patients who received radiotherapy (RT) were locally controlled. Only one of five Group III patients was locally controlled without RT. Conclusions: The overall prognosis of adult RMS is worse than reported in children, but age criteria within the adult population did not further classify outcome. RT is an effective local modality providing local control in almost all Group II and majority of Group III patients.

Highlights

  • Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in the pediatric population

  • The purpose of our study is to review our institutional experience with adult rhabdomyosarcoma in an effort to better define the presentation, prognostic factors and patterns of failure

  • Rhabdomyosarcoma is the most common soft tissue sarcoma in children accounting for approximately 400 cases per year in the United States

Read more

Summary

Introduction

Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in the pediatric population. The median age at diagnosis is 5 years, and the majority of reported cases are in children. As a result of the cooperative efforts of the Intergroup Rhabdomyosarcoma Study (IRS) Committee, children have expected 3-year overall and failurefree survival rates of 86 and 77%.1. The IRS trials have identified effective chemotherapy regimens and have more clearly delineated the roles of surgery and radiotherapy (RT). In a study from Memorial Sloan-Kettering Cancer Center, RMS comprised 2% of all soft tissue

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call